Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rexlemestrocel L - Mesoblast/Teva Pharmaceutical Industries

X
Drug Profile

Rexlemestrocel L - Mesoblast/Teva Pharmaceutical Industries

Alternative Names: Allogeneic mesenchymal precursor cells - Mesoblast; Allogeneic STRO-3 immunoselected bone marrow-derived mesenchymal precursor cells (MPCs) - Mesoblast; CEP-41750; Mesenchymal stem cell therapy - Mesoblast; MPC 06; MPC-06-ID; MPC-150; MPC-150-IM; MPC-25; MPC-25-IC; MPC-25-Osteo; MPC-300; MPC-300-IV; MPC-75-IA; MPC-CBE; MPC-MICRO-IO; MSB-CAR001; NeoFuse; Replicart; Revascor; Rexlemestrocel-L - Mesoblast/Teva Pharmaceutical Industries

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanson Institute; Institute of Medical and Veterinary Science
  • Developer Angioblast Systems; Boston Childrens Hospital; Mesoblast; Teva Pharmaceutical Industries
  • Class Anti-inflammatories; Anti-ischaemics; Antihypercalcaemics; Antineoplastics; Antirheumatics; Heart failure therapies; Mesenchymal stem cell therapies; Skin disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell replacements; Osteogenesis stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies; Hypoplastic left heart syndrome; Heart failure
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Back pain; Heart failure; Hodgkin's disease; Intervertebral disc degeneration; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Myocardial infarction; Osteoarthritis; Rheumatoid arthritis; Spondylosis; Type 2 diabetes mellitus
  • Phase I/II Diabetic nephropathies; Hypoplastic left heart syndrome
  • No development reported Age-related macular degeneration; Fracture; Lung disorders; Peripheral arterial disorders; Skin ulcer

Most Recent Events

  • 30 Apr 2024 Mesoblast announces intention to submit BLA to the US FDA for Hypoplastic left heart syndrome
  • 30 Apr 2024 Mesoblast plans a phase III trial for Back pain and Intervertebral disc degeneration in May 2024 in USA and Europe (Intralumbar, Injection) (NCT06325566)
  • 11 Mar 2024 Mesoblast announces intention to request a pre-BLA meeting with FDA to discuss data presentation, timing and FDA expectations for an accelerated approval filing in end-stage ischemic HFrEF patients with LVAD implantation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top